secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001140361-23-037767
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M
--------------------------------------------------------------------------------

- ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.
- Full-year 2023 ARIKAYCE revenue guidance raised to $295-305M from $285-300M.
- Net loss $244.8M ($1.78/sh) vs $95.6M loss in Q2 2022; R&D costs rose due to $76.5M acquisition of Adrestia.
- Cash, equivalents, marketable securities $918M as of June 30, down from $999M at March 31.
- Upcoming catalysts: ARISE topline data Sept 2023; ASPEN Phase 3 data expected Q2 2024; TPIP interim data H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/0001140361-23-037767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/brhc20056931_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-037767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer